# A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Source: https://onco.cc/trials/nct07462377/  
OnCo record `nct07462377` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of EPI-326 run by EpiBiologics, now recruiting.

## Summary

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC is a phase 1 interventional study registered as NCT07462377 by EpiBiologics, with 110 participants planned, started 2026-03-31. Conditions recorded: Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC and EGFR. Interventions recorded: EPI-326.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07462377
- Phase: 1
- Setting: A First-in-Human, Open-label, Multicenter, Phase 1 Study of EPI-326 in Patients With Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma
- Sponsor: EpiBiologics
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT07462377: https://clinicaltrials.gov/study/NCT07462377

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [EPI-326](https://onco.cc/drugs/epi-326/)
- companies: [EpiBiologics](https://onco.cc/companies/epibiologics/)

---
JSON: https://onco.cc/api/v1/entities/nct07462377.json